Drug Trial Radar · NCT06863740
Using Cannabis to Treat Restless Legs Syndrome
Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jul 25, 2025
Primary completion
Dec 2026
Study completion May 2027
Sponsor
- Lead sponsor
- Sunnybrook Health Sciences CentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University Health Network, Toronto
- First posted
- Mar 7, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Restless Legs Syndrome (RLS) is a disorder that causes painful and uncomfortable sensations in the legs, and its symptoms have a significant impact on sleep and quality of life. Cannabis has been used by some RLS patients as a treatment due to its painkilling and drowsiness effects, however there has never been a clinical research trial investigating cannabis in patients with RLS. A controlled trial is needed to establish how safe and feasible cannabis is as a treatment for RLS. The investigators plan to randomize 30 participants with moderate-to-severe RLS to receive either cannabis or placebo for 8 weeks. The investigators will measure patients sleep quality and quality of life at baseline and 8-week follow-up. The investigators will also monitor patients for any adverse reactions to the study drug.
Conditions
- Restless Leg Syndrome (RLS)
Interventions
Cannabis oilDrug
5:1 CBD:THC oral formulation with a concentration of 25 mg/g CBD and 5 mg/g THC in a pharmaceutical grade medium chain triglyceride (MCT) oil.
Cannabis placeboDrug
Placebo oil
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events and Serious Adverse EventsTime frame: 8 weeks
- Rate of Study CompletionTime frame: 8 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada · Recruiting
University Health Network
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.